Swedish-Nature-09-1248x672

iLite ADCC & ADCP Bioassays

Effector and Target cells engineered to work optimally together – a system that is greater than the sum of its parts

Assay-development-504x672

Greater than the sum of its parts

ADCC and ADCP Bioassays

Many antibody-based therapeutics rely, at least in part, on their ability to induce ADCC or ADCP in patients. Our ADCC and ADCP assays are based on iLite® technology, a cleverly engineered cell-based system with a dual reporter gene readout. They offer a convenient and powerful way of measuring the efficacy of antibodies to elicit ADCC or ADCP in vitro.

iLite ADCC & ADCP Reporter Gene Assays

iLite Fc Effector Activity Bioassays are reporter gene cell lines and antigen-specific target cells designed to measure the Fc effect of antibodies and other biologics. These bioassays utilize a luciferase reporter gene system to conveniently assess the efficacy of antibodies in eliciting ADCC and ADCP in vitro.

  • Biologically relevant MoA-reflective assays
  • Unparalleled sensitivity for each target
  • A rapid and convenient workflow with reduced assay variability
  • Assays suitable for antibody screening, characterization, stability, and potency studies
  • A secondary reporter gene that acts as an internal control, compensating for differences in cell number and matrix effects
  • "Assay-ready" format for rapid and convenient use
  • Effector and Target cells engineered to work optimally together

Our ADCC & ADCP Reporter-Gene Assays

FILTER VIEW
ALL ADCC ADCP Effector Cells Target cells
QUICK SEARCH
BM5001

iLite® ADCC Effector FcγRIIIa (V)

Designed to quantify ADCC activity

CELL-BASED
arrow
Cell-based reporter gene bioassay | Fc Effector Cells | BM5001 | ADCC | Cell-based reporter gene assay | Luminescence |
BM5004

iLite® ADCP Effector FcγRIIa

Accurate measurement of ADCP activity

CELL-BASED
arrow
Cell-based reporter gene bioassay | Fc Effector Cells | BM5004 | ADCP | Cell-based reporter gene assay | Luminescence |
BM5025

iLite® CD19 (+) Target

Engineered to express CD19, this cell line is ideal for ADCC and bispecific antibody assays

CELL-BASED
arrow
Cell-based reporter gene bioassay | Target Cells | BM5025 | ADCC | T-Cell Activation | Cell-based reporter gene assay | Luminescence |
BM5026

iLite® CD19 (-) Target

CD19-negative target cell line used as a specificity control in ADCC and T cell engager assays

CELL-BASED
arrow
Cell-based reporter gene bioassay | Target Cells | BM5026 | ADCC | T-Cell Activation | Cell-based reporter gene assay | Luminescence |
BM5010

iLite® CD20 (+) Target

Target cells expressing CD20 for use in ADCC and ADCP bioassays

CELL-BASED
arrow
Cell-based reporter gene bioassay | Target Cells | BM5010 | ADCC | ADCP | Cell-based reporter gene assay | Luminescence |
BM5015

iLite® CD20 (-) Target

CD20-negative target cells. Ideal for use as controls in CD20-specific bioactivity assays

CELL-BASED
arrow
Cell-based reporter gene bioassay | Target Cells | BM5015 | ADCC | ADCP | Cell-based reporter gene assay | Luminescence |
BM5035

iLite® EGFR (+) Target

Well-suited for ADCC or bispecific antibody assays targeting EGFR-positive cells

CELL-BASED
arrow
Cell-based reporter gene bioassay | Target Cells | BM5035 | ADCC | Cell-based reporter gene assay | Luminescence |
BM5036

iLite® EGFR (-) Target

A negative control cell line for EGFR-targeted bioassays

CELL-BASED
arrow
Cell-based reporter gene bioassay | Target Cells | BM5036 | ADCC | Cell-based reporter gene assay | Luminescence |
BM5011

iLite® HER2 (+) Target

Target cells for functional antibody testing in HER2-targeted bioassays

CELL-BASED
arrow
Cell-based reporter gene bioassay | Target Cells | BM5011 | ADCC | ADCP | Cell-based reporter gene assay | Luminescence |
BM5016

iLite® HER2 (-) Target

HER2-negative target cell line used as a control in HER2 bioactivity, ADCP, and ADCC assays

CELL-BASED
arrow
Cell-based reporter gene bioassay | Target Cells | BM5016 | ADCC | ADCP | Cell-based reporter gene assay | Luminescence |
BM5013

iLite® mTNF-alpha (+) Target

Target cells for functional characterization of TNF-targeting biologics

CELL-BASED
arrow
Cell-based reporter gene bioassay | Target Cells | BM5013 | ADCC | ADCP | Cell-based reporter gene assay | Luminescence |
BM5014

iLite® mTNF-alpha (-) Target

A control cell line used for specificity assessment in TNF-targeted assays

CELL-BASED
arrow
Cell-based reporter gene bioassay | Target Cells | BM5014 | ADCC | ADCP | Cell-based reporter gene assay | Luminescence |
BM5017

iLite® mVEGF (+) Target

Target cells for potency assays of anti-VEGF agents

CELL-BASED
arrow
Cell-based reporter gene bioassay | Target Cells | BM5017 | ADCC | Cell-based reporter gene assay | Luminescence |
BM5018

iLite® mVEGF (-) Target

Negative control cell line for VEGF-targeted assays

CELL-BASED
arrow
Cell-based reporter gene bioassay | Target Cells | BM5018 | ADCC | Cell-based reporter gene assay | Luminescence |

Didn't find what you were looking for?

We offer products customized to your needs. Our custom iLite® reporter-gene assays can be adapted to almost any target. We also offer custom ELISA plates and other products. In addition, you can take advantage of our service offerings and let us do the work for you.

Contact Us

iLite News

previous
Introducing the new iLite® C3a Assay Ready Cells

1 DECEMBER 2025

Introducing the new iLite® C3a Assay Ready Cells

Read post
Take advantage of a more comprehensive way of looking at AAV Immunogenicity – With a Partner Who Gets the full picture

6 AUGUST 2025

Take advantage of a more comprehensive way of looking at AAV Immunogenicity – With a Partner Who Get...

Read post
Introducing the AAV Complement Activation Assay: A New Standard in Safety Assessment for Gene Therapies

10 JULY 2025

Introducing the AAV Complement Activation Assay: A New Standard in Safety Assessment for Gene Therap...

Read post
Advancing Gene Therapy Research with iLite Assay Ready Cells for AAV Neutralizing Antibody Detection

2 JULY 2025

Advancing Gene Therapy Research with iLite Assay Ready Cells for AAV Neutralizing Antibody Detection

Read post
AAV Safety Assay Platform: The Immunogenicity Trifecta - NAb, TAb & Complement

30 JUNE 2025

AAV Safety Assay Platform: The Immunogenicity Trifecta - NAb, TAb & Complement

Read post
next
See more news >

iLite Downloads

previous
Mechanism-linked potency assays drive Gene Therapy success

Editorial article

Mechanism-linked potency assays drive Gene Therapy success

Read post
Addressing the analytical gaps in modern therapeutic development

White Paper Application Story

Addressing the analytical gaps in modern therapeutic development

Read post
Partnering for success in advanced therapeutics

Partnering for success in advanced therapeutics

Read post
Case Study: How iLite® Technology Enhances Immunogenicity Testing

Case Story

Case Study: How iLite® Technology Enhances Immunogenicity Testing

Read post
Ensuring Quality and Unmatched Adaptability When Assessing Neutralizing Antibodies in AAV-Mediated Gene Therapy

White Paper

Ensuring Quality and Unmatched Adaptability When Assessing Neutralizing Antibodies in AAV-Mediated G...

Read post
next
See more assets >

“Wieslab® Complement System Screen is a multifunctional ELISA kit for reliably detecting complement deficiencies of all three pathways selectively, but also for assessing complement activation in research applications”.

– Some Person

326
refs

Contact our iLite team

Write us a message and a product specialist will get in touch